Abstracts Archive - Page 2569 of 2607 - ACR Meeting Abstracts

Abstract Number: 523 • 2012 ACR/ARHP Annual Meeting
Use of Global Gene Expression Profiling to Characterize Sjögren’s Patients Who Underexpress Interferon-Inducible Genes
John A. Ice¹, He Li², Jennifer A. Kelly¹, Indra Adrianto¹, Stuart B. Glenn³, Kimberly S. Hefner⁴, Evan G. Vista⁵, Donald U. Stone⁶, Raj Gopalakrishnan⁷, Glen D. Houston⁸, David M. Lewis⁹, Michael Rohrer⁷, Pamela Hughes⁷, John B. Harley¹⁰, Courtney G. Montgomery¹¹, James Chodosh¹², James A. Lessard¹³, Juan-Manuel Anaya¹⁴, Barbara M. Segal¹⁵, Nelson L. Rhodus¹⁶, Lida Radfar¹⁷, Mark B. Frank¹, R. Hal Scofield¹⁸, Christopher J. Lessard¹⁹ and Kathy Moser Sivils¹, ¹Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁵Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁶Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁸Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹³Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁴School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹⁵Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth. We previously reported overexpression of interferon-inducible (IFI) genes…
Abstract Number: 524 • 2012 ACR/ARHP Annual Meeting
RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts in Sjögren’s Syndrome
Indra Adrianto¹, Graham B. Wiley¹, John A. Ice¹, He Li¹, Jennifer A. Kelly², Astrid Rasmussen¹, Stuart B. Glenn³, Kimberly Hefner⁴, Donald U. Stone⁵, Raj Gopalakrishnan⁶, Glen D. Houston⁷, David M. Lewis⁸, Michael Rohrer⁶, James A. Lessard⁹, Juan-Manuel Anaya¹⁰, Barbara M. Segal¹¹, Nelson L. Rhodus¹², Lida Radfar¹³, John B. Harley¹⁴, Judith A. James², Courtney G. Montgomery¹, R. Hal Scofield¹⁵, Patrick M. Gaffney¹, Kathy Moser Sivils² and Christopher J. Lessard¹⁶, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁵Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁷Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁹Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁰School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹¹Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹²University of Minnesota, Minneapolis, MN, ¹³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁴Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. SS…
Abstract Number: 525 • 2012 ACR/ARHP Annual Meeting
Gene Expression Profiling in a Large Cohort of Europeans with Sjögren’s Syndrome Reveals Candidate Genes in Viral, Immune, and Interferon-Related Pathways
He Li¹, John A. Ice², Jennifer A. Kelly³, Indra Adrianto², Stuart B. Glenn⁴, Kimberly S. Hefner⁵, Evan G. Vista⁶, Donald U. Stone⁷, Raj Gopalakrishnan⁸, Glen D. Houston⁹, David M. Lewis¹⁰, Michael Rohrer⁸, Pamela Hughes⁸, John B. Harley¹¹, Courtney G. Montgomery², James Chodosh⁷, James A. Lessard¹², Juan-Manuel Anaya¹³, Barbara M. Segal¹⁴, Nelson L. Rhodus¹⁵, Lida Radfar¹⁶, Mark B. Frank¹⁷, R. Hal Scofield¹⁸, Christopher J. Lessard¹⁹ and Kathy Moser Sivils³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁷Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁹Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Valley Bone and Joint Clinic, Grand Forks, ND, ¹³School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS), characterized by lymphocytic infiltration of exocrine glands, is a progressive autoimmune exocrinopathy present in 0.7-1% of Europeans. To better understand the…
Abstract Number: 526 • 2012 ACR/ARHP Annual Meeting
Use of a Novel Probe to Demonstrate Granzyme B Activity in Sjogren’s Syndrome Salivary Glands
Kimberly Doering Maurer¹, Laura Gutierrez-Alamillo¹, Efstathia K. Kapsogeorgou², Athanasios G. Tzioufas³, Livia Casciola-Rosen⁴ and Antony Rosen⁴, ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Pathophysiology, School of Medicine, National University of Athens, Greece, Athens, Greece, ³Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ⁴Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Salivary glands are a prominent target organ in Sjögren’s syndrome (SS), with patients having abnormal secretory function and inflammatory infiltration of these glands. Little…
Abstract Number: 527 • 2012 ACR/ARHP Annual Meeting
Multiplexed Nanostring Screening for Salivary Gland Viral Elements in Sjogren’s Syndrome
Kristin Haffizulla¹, Glen Barber², Juan Chen³ and Eric L. Greidinger⁴, ¹Internal Medicine, University of Miami Miller School of Medicine, Miami, FL, ²Virology, University of Miami Miller School of Medicine, Miami, FL, ³Rheumatology, The First Afflicted Hospital of Xiamen University, China, Miami, FL, ⁴Rheumatology, University of Miami, Miami, FL
Background/Purpose: To test the hypothesis that viruses are associated with Sjogren’s syndrome, salivary gland RNA extracts from Sjogren’s patients and non-Sjogren’s controls were screened for…
Abstract Number: 528 • 2012 ACR/ARHP Annual Meeting
Mxa As a Biomarker for Systemic Interferon Type I Activation in Primary Sjögren′s Syndrome
Naomi I. Maria¹, Zana Brkic¹, Matti Waris², Cornelia G. van Helden-Meeuwsen¹, Kim Heezen¹, Joop P. van de Merwe¹, Paul L. van Daele³, Virgil A. Dalm³, Hemmo A. Drexhage³ and Marjan A. Versnel³, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Department of Virology, University of Turku, Turku, Finland, ³Erasmus Medical Center, Immunology, Rotterdam, Netherlands
Background/Purpose: To establish an easy and practical assay for detection of systemic Interferon (IFN) type I activation in primary Sjögren's syndrome (pSS). The monocyte IFN…
Abstract Number: 529 • 2012 ACR/ARHP Annual Meeting
The Axis P2X7 Receptor-Inflammasome: A Role in Modulating Inflammatory Response in Primary Sjögren’s Syndrome?
Chiara Baldini¹, Chiara Rossi¹, Eleonora Santini¹, Francesco Ferro¹, Alessia Gallo², Daniela Martini¹, Francesca Sernissi¹, Valentina Donati¹, Camillo Giacomelli¹, Nicoletta Luciano¹, Anna Solini¹ and Stefano Bombardieri¹, ¹Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Sjogren's Clinic, NIDCR, Bethesda, MD
Background/Purpose: The exact cause of exocrine gland dysfunction in primary Sjögren’s syndrome (pSS) has not been fully delineated, but it is thought that both innate…
Abstract Number: 490 • 2012 ACR/ARHP Annual Meeting
12- and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Douglas E. Schlichting², Kimberly L. Sterling³, Edward Keystone⁴, Peter Taylor⁵, Mark C. Genovese⁶, Louise Johnson⁷, Juan C. Rizo Rodriguez⁸, Chin H. Lee² and Carol L. Gaich³, ¹Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, ⁴University of Toronto, Toronto, ON, Canada, ⁵Kennedy Institute of Rheumatology, London, United Kingdom, ⁶Division of Rheumatology, Stanford University, Palo Alto, CA, ⁷PharmaNet/i3, Eden Prairie, MN, ⁸Clinical Investigation, Centro de Alta Especialidad en Reumatología e Investigación del Potosí, San Luis Potosi, San Luis Potosi, Mexico
Background/Purpose: Baricitinib (formerly, LY3009104/INCB028050) is a novel, oral inhibitor of the JAK1 and JAK2 in the JAK-STAT pathway known to be of importance in the…
Abstract Number: 491 • 2012 ACR/ARHP Annual Meeting
Predictors of Initiating Biologic Monotherapy in Biologic Naïve Patients with Rheumatoid Arthritis (RA) in a US Registry Population
Dimitrios A. Pappas¹, George W. Reed², Ani John³, Ashwini Shewade³, Katherine C. Saunders⁴, Jenny Devenport⁵, Jeffrey D. Greenberg⁶ and Joel M. Kremer⁷, ¹Columbia University, New York, NY, ²University of Massachusetts Medical School, Worcester, MA, ³Genentech Inc., South San Francisco, CA, ⁴Corrona, LLC., Southborough, MA, ⁵Genentech, South San Francisco, CA, ⁶Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Published data have shown that approximately one-third of patients with RA are treated with biologic (Bio) monotherapy (MT) (without concomitant DMARD) and a considerable…
Abstract Number: 492 • 2012 ACR/ARHP Annual Meeting
Divergent Toxicity of TNF Inhibitors On Demyelinating Disorders and Neurological Events
Sergio Schwartzman¹, John Clark² and John J. Cush³, ¹Rheumatology, Hosp for Special Surgery, New York, NY, ²RiskBenefits LLC, Flourtown, PA, PA, ³Baylor Research Institute, Dallas, TX
Background/Purpose: There are currently five anti-TNF agents that have been approved for various autoimmune illnesses. There is no convincing evidence that any one of these…
Abstract Number: 493 • 2012 ACR/ARHP Annual Meeting
Effect of Infliximab On Employment Status in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis
W. Bensen¹, J. Carter Thorne², Saeed A. Shaikh³, Maqbool K. Sheriff⁴, Susan M. Otawa⁵, Allen J. Lehman⁵ and Hayssam Khalil⁶, ¹St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, McMaster University, St Catharines, ON, Canada, ⁴Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁶Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with significant functional impairment and work disability. In the absence of treatment, approximately 80% of…
Abstract Number: 494 • 2012 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis?
William Bensen¹, Denis Choquette², Isabelle Fortin³, Alice V. Klinkhoff⁴, Susan M. Otawa⁵ and Hayssam Khalil⁶, ¹St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴The Mary Pack Arthritis Ctr, Vancouver, BC, Canada, ⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁶Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The prevalence of rheumatoid arthritis (RA) is 2-4 times higher in women compared to men depending on age. Furthermore, in women RA incidence increases…
Abstract Number: 495 • 2012 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
Sofia Ramiro¹, Frederick Wolfe², David J. Harrison³, George Joseph³, David H. Collier³, Désirée van der Heijde⁴, Robert Landewé⁵ and Kaleb Michaud⁶, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Amgen Inc., Thousand Oaks, CA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Since discontinuation may be a surrogate for ineffectiveness, we measured rates and reasons for biologic discontinuation in a real-world setting. Methods: From 1998 to…
Abstract Number: 496 • 2012 ACR/ARHP Annual Meeting
Real-World Effectiveness of Infliximab in Improving Routine Assessment of Patient Index Data 3 Outcomes: The Canadian Experience
Andrew Chow¹, Majed M. Khraishi², Jude F. Rodrigues³, Susan M. Otawa⁴ and Hayssam Khalil⁵, ¹University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ²Nexus Clinical Research, St John's, NF, Canada, ³Rheumatology, Windsor, ON, Canada, ⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The routine assessment of patient index data 3 (RAPID3) was recently designed as a pooled index of 3 patient-reported outcomes (PROs): physical function, pain…
Abstract Number: 497 • 2012 ACR/ARHP Annual Meeting
Golimumab Drug Utilization Patterns in Canada – Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab
Hayssam Khalil¹ and Amir Tahami², ¹Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ²Janssen Canada Inc., Toronto, ON, Canada
Background/Purpose: Golimumab is a monthly self-injected anti-tumor necrosis factor alpha therapy for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA). It…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].